<DOC>
	<DOCNO>NCT01675297</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Risedronate , cholecalciferol combination tablet patient Osteoporosis .</brief_summary>
	<brief_title>Efficacy Safety Study Risedronate , Cholecalciferol Combination Tablet Patients With Osteoporosis</brief_title>
	<detailed_description>The purpose study evaluate efficacy safety Risedronate without cholecalciferol vitamin D status , Bone Mineral Density ( BMD ) bone marker .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>1 . Male osteoporosis patient 19 year age 2 . Female osteoporosis patient menopause Definition osteoporosis They BMD Tscore 2.5 less mean Lumbar spine ( L1L4 ) , Femoral neck total . Or evidence least one vertebral fracture Definition menopause ( one three condition ) For 12months spontaneous amenorrhea For 6months spontaneous amenorrhea serum FSH ( Follicle stimulate hormone ) 40mlU/mL 6weeks bilateral ovariectomy whether hysterectomy . 1 . Patients esophagus disorder ( i.e : esophagostenosis ) 2 . Patients administered osteoporosis therapy ( except calcium , Vit.D medication ) within previous 3 Months 3 . Patients serum calcium concentration 8.0mg 4 . Patients severe nephropathy ( CCr 30mL/min less ) 5 . Patients unable sit upright stand 30minutes</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Risedronate , cholecalciferol , BMD</keyword>
</DOC>